M&T Bank
TVTX icon

M&T Bank’s Travere Therapeutics TVTX Stock Holding History

M&T Bank’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$325K Sell
10,953
-729
-6% -$21.8K ﹤0.01% 1329
2025
Q4 		$446K Buy
+11,682
New +$380K ﹤0.01% 1189

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

M&T Bank's TVTX Position: Q1 2026 in Review

M&T Bank reduced its Travere Therapeutics (TVTX) stake by 6.2% in Q1 2026, selling an estimated $21.8K and leaving 10,953 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

M&T Bank first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $446K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • M&T Bank held 10,953 shares of Travere Therapeutics worth $325K as of Q1 2026.
  • M&T Bank sold 729 Travere Therapeutics shares in Q1 2026, an estimated $21.8K.
  • Travere Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q1 2026, its #1329 holding.
  • M&T Bank first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • M&T Bank's Travere Therapeutics position peaked at $446K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.